Literature DB >> 18490248

Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin's diffuse large B-cell lymphoma.

J M Cervera Grau1, G Esquerdo Galiana, A Belso Candela, C Llorca Ferrándiz, A Juárez Marroquí, S Maciá Escalante.   

Abstract

Rituximab is a treatment option to non-Hodg kin's diffuse large B-cell lymphoma (NHDLBCL) in advanced stage and comorbility. It is known the cardiotoxicity effect of this drug, but there is no previous report describing a complete atrioventricular block (CAVB) secundary to treatment with Rituximab. We present an elderly woman treated with monotherapy with Rituximab who experienced a CAVB after administration of the fifth dose of this drug.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18490248     DOI： 10.1007/s12094-008-0201-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  6 in total

1.  [Neurohormones and cytokines in heart failure. Correlation with coronary flow reserve].

Authors:  Isabel Coma-Canella; Alfonso Macías; Nerea Varo; Alfonso Sánchez Ibarrola
Journal:  Rev Esp Cardiol       Date:  2005-11       Impact factor: 4.753

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  [A case of renal cell carcinoma complicated with interstitial pneumonitis, complete A-V block and pleural effusion during interferon-alpha therapy].

Authors:  K Tsushima; S Yamaguchi; K Furihata; J Hotta; M Sasabayashi; K Urushihata; S Takashi; A Tsukadaira; Y Yamazaki; E Satou; M Hanaoka; T Koizumi; K Fujimoto; Y Ohkubo; K Kubo
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2001-11

Review 4.  Mechanism of action of rituximab.

Authors:  Thomas Cerny; Bettina Borisch; Martino Introna; Peter Johnson; Andrea L Rose
Journal:  Anticancer Drugs       Date:  2002-11       Impact factor: 2.248

5.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

6.  A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'.

Authors:  J Rodríguez; F Cabanillas; P McLaughlin; F Swan; M Rodríguez; F Hagemeister; J Romaguera
Journal:  Ann Oncol       Date:  1992-11       Impact factor: 32.976
  6 in total
  5 in total

Review 1.  Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Mauro Galeazzi; Franco Laghi-Pasini
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Rituximab induced left bundle branch block.

Authors:  Mujeeb Sheikh; Ankush Moza; Blair P Grubb
Journal:  Heart Views       Date:  2015 Jan-Mar

3.  Cardiac Lymphoma: After the Hurricane.

Authors:  Marijana Tadic; Sabine Haßfeld; Burket Pieske; Martin Genger
Journal:  Chin Med J (Engl)       Date:  2017-10-05       Impact factor: 2.628

Review 4.  Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives.

Authors:  Jialin Duan; Jingwen Tao; Maocai Zhai; Chengpeng Li; Ning Zhou; Jiagao Lv; Lin Wang; Li Lin; Rong Bai
Journal:  Oncotarget       Date:  2018-05-22

5.  Bradyarrhythmias in Cardio-Oncology.

Authors:  Marta Fonseca; Evaline Cheng; Duc Do; Shouvik Haldar; Shelby Kutty; Eric H Yang; Arjun K Ghosh; Avirup Guha
Journal:  South Asian J Cancer       Date:  2021-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.